EFFECT OF AGMATINE ON 6-HYDROXYDOPAMINE INDUCED MEMORY IMPAIRMENT IN PARKINSON’S DISEASE IN RODENTS

The core finding of the present preclinical study demonstrated that, administration of increasing doses of Agmatine is remarkably neuroprotective in male wistar rats against 6-Hydroxydopamine induced neurotoxicity. Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disease with multiple motor and non-motor features that contribute to the impairment of health-related quality of life (QOL). It is associated with the loss of brown pigment neuromelanin with preferential loss of the dopaminergic neurons of the substantia nigra pars compacta results in oxidative stress and mitochondrial dysfunction. It is characterized by reduced movement, rigidity, and tremor. Agmatine (AGM) (1-Amino-4-guanidinobutane, 4 (Aminobutyl) Guanidine,1- guanidinobutane) pharmacological and electrophysiological evidence indicate that Agmatine act at N-methyl-d-aspartate (NMDAr) and nitric acid synthase (NOS) to exert anti-excitatory effects throughout the central nervous system. Agmatine act as neuroprotective agent & memory enhancer. Relevent doses of Agmatine treatment protects behavioural changes, significantly attenuated oxidative damage & improved mitochondrial complexs enzyme activities in different regions (striatum, cortex and hippocampus) of rat brain against 6-OHDA induced neurotoxicity. I.C.V. administration of 6-Hydroxydopamine is known to produce hypo activity that resembles juvenile onset and advanced Parkinson’s disease in rats. The results show that Agmatine treatment is effective in various behavioral models, it could be used as an effective therapeutic agent in the management of Parkinson’s disease and related conditions and thus it shows the effect of Agmatine on 6-Hydroxydopamine induced memory impairment in Parkinson’s disease in Rodents.